Table 2.
Pre-vaccination HPV prevalence (WHINURS) by LA and post-vaccination prevalence (Compass pilot) by 10-year age groups as determined by LA, cobas and cobas/LA.ⱡ
| HPV type | Age | Pre-vaccination |
Post-vaccination |
|||||||
|---|---|---|---|---|---|---|---|---|---|---|
| LA |
LA |
cobas (2019) |
cobas/LAa |
|||||||
| +ve/N | Pr | N | +ve | Pr (95%CI) | +ve | Pr (95%CI) | +ve | Pr (95%CI) | ||
|
HPV16 |
25–34 | 77/1010 | 7.62% (6.06–9.44) | 727 | 8 | 1.10% (0.48–2.16) | 8 | 1.10% (0.48–2.16) | 9 | 1.24% (0.57–2.34) |
| 35–44 | 11/578 | 1.90% (0.95–3.38) | 935 | 13 | 1.39% (0.74–2.37) | 11 | 1.18% (0.59–2.10) | 13 | 1.39% (0.74–2.37) | |
| 45–54 | 5/270 | 1.85% (0.60–4.27) | 794 | 8 | 1.01% (0.44–1.98) | 6 | 0.76% (0.28–1.64) | 6 | 0.76% (0.28–1.64) | |
| 55–64 | 1/75 | 1.33% (0.03–7.21) | 533 | 5 | 0.94% (0.31–2.18) | 3 | 0.56% (0.12–1.64) | 4 | 0.75% (0.20–1.91) | |
| Total | 94/1933 | 4.86% (3.95–5.92) | 2989 | 34 | 1.14% (0.79–1.59) | 28 | 0.94% (0.62–1.35) | 32 | 1.07% (0.73–1.51) | |
| aPR 3.38% (95%CI 2.55–4.32), SE (aPR): 0.42% |
aPR 1.13% (95%CI 0.75–1.51), SE (aPR): 0.19% |
aPR 0.94% (95%CI 0.59–1.29), SE (aPR): 0.18% |
aPR 1.07% (95%CI -.70-1.51) SE (aPR): 0.19% |
|||||||
|
HPV16/18 |
25–34 | 104/1010 | 10.30% (8.49–12.34) | 727 | 13 | 1.79% (0.96–3.04) | 16 | 2.20% (1.26–3.55) | 17 | 2.34% (1.37–3.72) |
| 35–44 | 17/578 | 2.94% (1.72–4.67) | 935 | 21 | 2.25% (1.40–3.41) | 17 | 1.82% (1.06–2.90) | 19 | 2.03% (1.23–3.16) | |
| 45–54 | 7/270 | 2.59% (1.05–5.27) | 794 | 10 | 1.26% (0.61–2.30) | 8 | 1.01% (0.44–1.98) | 8 | 1.01% (0.44–1.98) | |
| 55–64 | 2/75 | 2.67% (0.32–9.30 | 533 | 6 | 1.13% (0.41–2.43) | 3 | 0.56% (0.12–1.64) | 4 | 0.75% (0.20–1.91) | |
| Total | 130/1933 | 6.73% (5.65–7.93) | 2989 | 50 | 1.67% (1.24–2.20) | 44 | 1.47% (1.07–1.97) | 48 | 1.61% (1.19–2.12) | |
| aPR 4.85% (95%CI 3.81–5.89), SE (aPR): 0.53% |
aPR 1.67% (95%CI 1.21–2.13), SE (aPR): 1.21% |
aPR 1.49% (95%CI 1.05–1.93), SE (aPR): 0.22% |
aPR 1.63% (95%CI 1.17–2.08), SE (aPR): 0.23% |
|||||||
|
Non-16/18 HPV types |
25–34 | 172/1010 | 17.03% (14.76–19.49) | 727 | 105 | 14.44% (11.97–17.21) | 105 | 14.44% (11.97–17.21) | 104 | 14.31% (11.84–17.06) |
| 35–44 | 59/578 | 10.21% (7.86–12.97) | 935 | 62 | 6.63% (5.12–8.42) | 59 | 6.31% (4.84–8.06) | 57 | 6.10% (4.65–7.83) | |
| 45–54 | 16/270 | 5.93% (3.42–9.45) | 794 | 32 | 4.03% (2.77–5.64) | 23 | 2.90% (1.84–4.31) | 23 | 2.90% (1.84–4.31) | |
| 55–64 | 7/75 | 9.33% (3.84–18.29) | 533 | 13 | 2.44% (1.30–4.13) | 12 | 2.25% (1.17–3.90) | 11 | 2.06% (1.03–3.66) | |
| Total | 254/1933 | 13.14% (11.67–14.73) | 2989 | 212 | 7.09% (6.20–8.07) | 199 | 6.66% (5.79–7.61) | 195 | 6.52% (5.66–7.47) | |
| aPR 10.85% (95%CI 9.17–12.52), SE (aPR): 0.85% |
aPR 7.39% (95%CI 6.45–8.34), SE (aPR): 0.48% |
aPR 6.97% (95%CI 6.05–7.90), SE (aPR): 0.47% |
aPR 6.84% (95%CI 5.93–7.75), SE (aPR): 0.47% |
|||||||
|
HPV types in 9V vaccine (16,18, 31, 33, 45, 52, 58) |
25–34 | 727 | 59 | 8.12% (6.24–10.34) | 57 | 7.84% (5.99–10.04) | ||||
| 35–44 | 935 | 55 | 5.88% (4.46–7.59) | 47 | 5.03% (3.72–6.63) | |||||
| 45–54 | Not applicableb | 794 | 22 | 2.77% (1.74–4.17) | Not applicableb | 16 | 2.02% (1.16–3.25) | |||
| 55–64 | 533 | 13 | 2.44% (1.30–4.13) | 10 | 1.88% (0.90–3.42) | |||||
| Total | 2989 | 149 | 4.98% (4.23–5.83) | 130 | 4.35% (3.65–5.14) | |||||
| aPR 5.09% (95%CI 4.30–5.89), SE (aPR): 0.41% |
aPR 4.48% (95%CI 3.73–5.23), SE (aPR): 0.38% |
|||||||||
|
Non-16/18 HPV in 9V vac(31,33, 45,52,58) |
25–34 | 727 | 46 | 6.33% (4.67–8.35) | 40 | 5.50 (3.96–7.42) | ||||
| 35–44 | Not applicableb | 935 | 34 | 3.64% (2.53–5.04) | Not applicableb | 28 | 2.99 (2.00–4.30) | |||
| 45–54 | 794 | 12 | 1.51% (0.78–2.63) | 8 | 1.01 (0.44–1.98) | |||||
| 55–64 | 533 | 7 | 1.31% (0.53–2.69) | 6 | 1.13 (0.41–2.43) | |||||
| Total | 2989 | 99 | 3.31% (2.70–4.02) | 82 | 2.74 (2.13–3.39) | |||||
| aPR 3.43% (95%CI 2.76–4.09), SE (aPR): 0.34% |
aPR 2.85% (95%CI 2.24–3.46), SE (aPR): 0.31% |
|||||||||
| All onco-genic HPV | 25–34 | 276/1010 | 27.33% (24.60–30.19) | 727 | 118 | 16.23% (13.62–19.12) | 121 | 16.64% (14.01–19.55) | 121 | 16.64% (14.01–19.55) |
| 35–44 | 76/578 | 13.15% (10.50–16.18) | 935 | 83 | 8.88% (7.13–10.89) | 76 | 8.13% (6.46–10.07) | 76 | 8.13% (6.46–10.07) | |
| 45–54 | 23/270 | 8.52% (5.48–12.51) | 794 | 42 | 5.29% (3.84–7.08) | 31 | 3.90% (2.67–5.50) | 31 | 3.90% (2.67–5.50) | |
| 55–64 | 9/75 | 12.00% (5.64–21.56) | 533 | 19 | 3.56% (2.16–5.51) | 15 | 2.81% (1.58–4.60) | 15 | 2.81% (1.58–4.60) | |
| Total | 384/1933 | 19.87% (18.11–21.72) | 2989 | 262 | 8.77% (7.78–9.84) | 243 | 8.13% (7.17–9.17) | 243 | 8.13% (7.17–9.17) | |
| aPR 15.70% (95%CI 13.79–17.60), SE (aPR): 0.97% | aPR 9.06% (95%CI 8.02–10.09), SE (aPR): 0.53% | aPR 8.47% (95%CI 7.47–9.47), SE (aPR): 0.51% | aPR 8.47% (95%CI 7.47–9.47), SE (aPR): 0.51% | |||||||
aPR: age-standardised prevalence rate; LA: linear array; N: number; Pr: prevalence; SE: standard error; +ve: positive; 9V: nonavalent.
HPV types for cobas; similarly, results provided by WHINURS for non-16/18 types were pooled.
ⱡ Results for algorithms A and B are presented in Supplementary Table S3.
a
Cobas/LA: cobas all samples/LA for cobas positive non-16/18HPV samples only.
b
Prevalence for HPV types included in the nonavalent vaccine could not be determined as positivity for non-16/18 HPV positive samples is pooled and cannot distinguish between individual.